Dulaglutide

Last Updated: 02/24/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1097 publications

Correction to "Cardiovascular Effectiveness of Semaglutide Versus Dulaglutide in Type 2 Diabetes".

Correction to "Cardiovascular Effectiveness of Semaglutide Versus Dulaglutide in Type 2 Diabetes".

Journal: Pharmacoepidemiology and drug safety
Published: January 22, 2026

Calculating cost per event avoided using a composite number needed to treat.

Calculating cost per event avoided using a composite number needed to treat.

Journal: Journal of medical economics
Published: January 21, 2026

Annals On Call - Dulaglutide, Semaglutide, and Tirzepatide: How Do Gastrointestinal Adverse Effects Compare?

Annals On Call - Dulaglutide, Semaglutide, and Tirzepatide: How Do Gastrointestinal Adverse Effects Compare?

Journal: Annals of internal medicine
Published: January 19, 2026

Cutaneous Adverse Events Associated With GLP-1 Receptor Agonists: A FAERS Database Analysis From 2018-2024.

Cutaneous Adverse Events Associated With GLP-1 Receptor Agonists: A FAERS Database Analysis From 2018-2024.

Journal: Journal of drugs in dermatology : JDD
Published: January 06, 2026

Unmasking the risk: euglycemic diabetic ketoacidosis induced by GLP-1 agonist in type 2 diabetes.

Unmasking the risk: euglycemic diabetic ketoacidosis induced by GLP-1 agonist in type 2 diabetes.

Journal: Proceedings (Baylor University. Medical Center)
Published: January 05, 2026

Clinical Manifestations.

Clinical Manifestations.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: December 25, 2025

Glucagon-Like Peptide-1 Receptor Agonists in Plastic Surgery: Perioperative Considerations and Safety Protocols.

Glucagon-Like Peptide-1 Receptor Agonists in Plastic Surgery: Perioperative Considerations and Safety Protocols.

Journal: Cureus
Published: December 22, 2025

Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.

Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.

Journal: The New England journal of medicine
Published: December 17, 2025

The concentration-dependent protective effects by new generation hypoglycemic agents on delirium, depression, dementia and coma: evidence from a network meta-analysis.

The concentration-dependent protective effects by new generation hypoglycemic agents on delirium, depression, dementia and coma: evidence from a network meta-analysis.

Journal: Journal of the Royal Society of Medicine
Published: December 08, 2025

Acute Kidney Injury from Mononuclear Cell-Predominated Interstitial Nephritis After Introduction of a Glucagon-Like Peptide-1 Receptor Agonist: A Case Report.

Acute Kidney Injury from Mononuclear Cell-Predominated Interstitial Nephritis After Introduction of a Glucagon-Like Peptide-1 Receptor Agonist: A Case Report.

Journal: The American journal of case reports
Published: December 07, 2025

Noninsulin drugs for type 2 diabetes.

Noninsulin drugs for type 2 diabetes.

Journal: The Medical letter on drugs and therapeutics
Published: November 19, 2025

Comparison chart: GLP-1 and GIP/GLP-1 receptor agonists for type 2 diabetes.

Comparison chart: GLP-1 and GIP/GLP-1 receptor agonists for type 2 diabetes.

Journal: The Medical letter on drugs and therapeutics
Published: November 19, 2025
Showing 1-12 of 1,097

Last Updated: 02/24/2026